Army enters partnership to create MERS vaccine

New partnership to create MERS vaccine
New partnership to create MERS vaccine | Courtesy of
GeneOne Life Science and the Walter Reed Army Institute of Research (WRAIR) recently developed a partnership to create a vaccine to protect people from Middle East respiratory syndrome (MERS).

The cooperative research and development agreement is specifically to further GLS-5300, the DNA vaccine from GeneOne to prevent MERS. The human trial of this vaccine will be the first for a MERS treatment or vaccine.

"It is very important we seize the opportunity to advance promising MERS vaccine candidates into human trials,” Col. Stephen Thomas, an infectious diseases physician and WRAIR's deputy commander of operations, said. “We want to understand this vaccine's safety and potential to protect as soon as possible. I believe U.S. military personnel could be at risk in the event of a large scale MERS outbreak. For this reason, I am glad we will collaborate with GeneOne to take the next steps in developing this vaccine candidate.”

The trial will be conducted at the Clinical Trials Center for WRAIR.

"We are pleased to collaborate with the world-class clinicians and scientists at Walter Reed Army Institute of Research,” GeneOne CEO Young Park said. “Our partnership with WRAIR will be a catalyst to rapidly advance MERS vaccine development. GeneOne is taking a leading role responding to the MERS health crisis and stands ready to advance other DNA vaccines for challenging infectious diseases."

Organizations in this Story

GeneOne Life Science

Want to get notified whenever we write about GeneOne Life Science ?
Next time we write about GeneOne Life Science, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.